查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836973

RNA疗法市场按治疗领域、给药系统和最终用户划分－2025-2032年全球预测

RNA Therapy Market by Therapeutic Area, Delivery System, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，RNA 疗法市场将成长至 141.5 亿美元，复合年增长率为 23.55%。

主要市场统计数据
基准年2024年 26亿美元
预计年份：2025年 32.3亿美元
预测年份：2032年 141.5亿美元
复合年增长率 (%) 23.55%

这是一份全面的入门指南，阐述了RNA疗法、递送创新和监管演变的进展如何汇聚在一起，重新定义治疗药物的研发管道。

RNA疗法领域已从科学探索转变为现代生物医学的核心支柱，重塑了研究人员、临床医生和行业领袖开展治疗方法发现和开发的方式。传讯RNA、小干扰RNA、反义寡核苷酸及相关方法的进步，在广泛的适应症领域展现出治疗潜力，刺激了对平台技术、递送系统和专业生产能力的新投资。这种转变体现在加速的转化研究、产研策略合作以及对可扩展、可重复生产流程日益重视等。

技术日趋成熟，加之监管预期和临床证据要求不断变化，迫使研发人员改善临床研究设计、安全性监测方法和对照药物选择。同时，递送载体、製剂化学和分析方法的改进降低了新研发人员的进入门槛，同时也提高了产品差异化的标准。因此，企业现在优先考虑平台稳健性、跨适应症适用性以及在不同患者群体中展现一致性疗效的能力。

在相关人员评估后续步骤之际，该产业必须将科学进展与切实可行的营运计画结合。如今，生产能力、供应链韧性和监管参与与标靶选择和临床前疗效同等重要。简而言之，RNA疗法正处于一个关键的十字路口，科学前景必须与卓越的执行力相契合，才能转化为持续的临床和商业性成功。

深入分析递送平台、临床优先排序和经营模式的突破如何重塑RNA疗法生态系统和商业化策略。

RNA疗法领域正经历一系列变革时期，这些变革正在改变研发者和投资者的策略重点。基于脂质奈米颗粒的製剂和新兴的外泌体平台实现了以往难以实现的全身递送和组织靶向，而聚合物载体和病毒载体杂交体则为持续表达和局部疗效提供了互补的途径。这些递送技术的进步拓展了可治疗的适应症，影响了给药模式，并对生产要求产生了重大影响。

其次，临床关註明显转向复杂且以往难以治疗的疾病，而罕见疾病治疗则正利用基因静默和基因替代策略来应对高雪氏症、神经肌肉疾病和镰状细胞疾病等遗传性疾病。由于全球公共卫生优先事项以及RNA平台能够实现的快速反应，感染疾病应用，包括针对病毒感染的标靶疗法和新型抗菌RNA策略，仍具有重要的策略意义。

第三，随着以平台为中心的公司寻求透过授权、策略联盟和垂直整合来实现广泛的技术堆迭的收益，经营模式正在转变。合约开发和受託製造公司正在扩展其能力，以应对高浓度製剂和脂质奈米颗粒封装等问题；随着临床给药模式的演变，医院和诊所也以新的方式应用先进疗法。研究机构持续推动创新，建构了一个充满活力的创新管道，各部门之间的相互依存度日益增强。

最后，监管机构和支付方对证据的日益重视正在重塑打入市场策略。研发人员正投资于真实世界证据的产生、长期安全性监测和卫生经济学研究，以支持报销讨论和政策制定。总而言之，这些转变标誌着RNA疗法正从孤立的概念验证工作转向持续的、系统性的临床实践整合。

对关税如何改变RNA治疗项目的供应链、筹资策略、临床优先顺序和生产投资进行详细评估

美国可能在2025年实施的累积关税，将为RNA疗法相关企业带来复杂的营运和策略挑战。关税政策的发展可能会增加脂质、核苷酸、酵素和一次性耗材等关键原材料的到岸成本，并可能影响质体生产、微流体封装、层析法系统和无菌填充生产线等高价值资本设备的供应和定价。不断上涨的采购成本将迫使研发企业和契约製造製造商重新评估供应商关係、库存策略和采购地域，以确保专案按时完成并达到品质标准。

为了因应关税主导的成本压力，企业可能会加快供应链在地化进程，扩大关键投入品的国内生产，或透过谈判达成长期采购协议来稳定价格。虽然本地化可以降低跨境关税的影响，但通常需要大量的资本投入和较长的营运前置作业时间，尤其是在需要特殊製造流程或监管核准的情况下。因此，缺乏内部製造能力的小型开发商和研发机构可能会受到不成比例的影响，迫使它们更多地依赖本地契约製造和战略合作伙伴。

关税也可能影响临床开发决策。投入成本的增加可能促使申办者优化试验方案以减少每位患者的材料用量，优先考虑报销途径更明确的适应症，或根据资源密集程度调整项目顺序。对于医院和诊所而言，这可能会加重采购预算负担，并影响需要复杂交付和支援基础设施的先进治疗方法的推广週期。投资者和策略合作伙伴可能会仔细审查供应链计划的韧性以及在成本结构变化下扩大生产规模的可行性。

最后，与关税政策相关的政治和监管讯号可能具有声誉和战略意义。贸易紧张局势加剧可能促使跨国公司将製造地分散到多个地区，以避免受到单一地区政策变化的影响。同时，双边和多边对话可能为关键医疗用品的豁免和关税减免铺平道路，凸显了积极与政策制定者和行业协会沟通的重要性。简而言之，2025年的关税发展可能促使采购、生产策略、临床项目优先顺序等方面进行结构性调整，并对时间表和伙伴关係模式产生实际影响。

对治疗领域差异、递送平台权衡以及最终用户行为的严格审查将确定RNA干预措施的项目管道和开发重点。

细分领域的动态揭示了科学机会与商业性可行性的交汇点，阐明了企业在推进基于RNA的干预措施时必须面对的战术性选择。在分析治疗领域细分时，研发人员需要在广泛的适用性和特定适应症的复杂性之间取得平衡。心血管和代谢疾病计画追求全身给药和持续活性；遗传疾病疗法旨在针对一次性疾病进行精准的基因校正或定序；感染疾病策略区分细菌和病毒疗法；神经病学计画致力于解决血脑屏障的给药限制；而罕见疾病则专注于特定疾病，例如高雪氏症、神经肌肉疾病和镰状细胞病，这些疾病的临床终点和监管渠道需要定制化的证据包装。这种血脑障壁的异质性也导致了不同的研发时间表、安全性考量和商业性准入策略。

从递送系统细分的角度来看，这种对比更加鲜明。基于外泌体的策略有望实现生物天然递送和潜在的免疫隐蔽性，但其生产和表征面临挑战，需要先进的分析能力。脂质奈米颗粒技术因其已证实的可扩展性和成熟的监管先例，已成为许多系统性应用的实际解决方案，但需要严格控制辅料和过程参数。另一方面，病毒载体能够为某些应用实现稳健的基因转移，但补偿是免疫抗原性和复杂的监管审查。递送平台的选择不仅影响临床疗效，还决定了上游供应商的需求、设施设计以及监管申报所需的分析开发深度。

终端用户细分以切实的方式影响商业化和推广策略。生物技术公司通常主导创新和平台开发，专注于智慧财产权的累积和临床概念验证。製药公司则带来后期开发、监管经验和全球商业化基础设施，一旦临床证据和支付方证据一致，就能实现更广泛的市场进入。医院和诊所在推广需要特殊剂量、长期监测以及整合到现有诊疗路径中的治疗方法发挥着关键作用，它们的采购标准也越来越强调已证实的临床效用和营运可行性。研究机构仍然是发现和转化专业知识的重要来源，它们通常与产业界合作，以降低早期科学研究风险并加速新型平台的迭代。

综上所述，这些细分洞察凸显了在专案规划早期阶段协调治疗标靶、给药途径和终端使用者参与策略的必要性。如果研发人员能够明确考虑适应症特征、平台限制和终端使用者需求之间的相互作用，就能更好地设计出符合监管预期并加速临床应用的临床试验方案。

对美洲、欧洲、中东和非洲以及亚太地区的生态系统如何对创新、製造能力、监管合规性和准入策略产生不同影响进行全面的区域评估。

区域动态对RNA疗法的研究、开发和商业化过程中的商业考量有不同的影响。在美洲，健全的创业投资生态系统、领先的学术医疗中心和先进的製造基础设施为早期创新和快速临床转化提供了沃土。国家监管机构制定的监管路径强调严格的安全性和有效性证据，而能够对接专业契约製造製造商和服务供应商网路的计画则能加快临床试验的进程。

欧洲、中东和非洲的管理体制和支付结构各不相同，因此需要製定细緻入微的市场准入计画。欧洲的法规结构提倡集中审批管道，这有利于跨境核准，而该地区的医疗保健系统则强调成本效益和实际治疗价值。亚太新兴市场生物技术活动和临床试验参与度不断提高，这为註册和合作提供了机会，同时也需要协调一致的监管和报销策略。

亚太地区的特点是生产能力快速扩张、公共和私人部门对生物製药製造的大量投资，以及日益增长的熟练科学家和技术人员队伍。多个地区正在积极简化先进疗法的监管流程，并鼓励本土生产，从而加快本地研发计画的进程。然而，对区域供应链的依赖以及监管协调程度的不均衡，要求企业采取多元化的采购方式，并积极与监管机构沟通，以确保专案在多个司法管辖区顺利推进。

本文深入概述了平台领导、策略联盟、製造专业化和监管参与如何构成RNA治疗领域最有效组织的特征。

在RNA疗法领域领先的公司正透过平台深度、策略合作伙伴关係和生产能力的组合来脱颖而出。以平台为中心的创新者投资于基础技术，以实现跨多个适应症的快速迭代，并优先考虑模组化设计、可靠的表征方法以及支援监管讨论的资料包封装。具有竞争力的研发和生产公司正在拓展脂质奈米颗粒製剂、分析方法开发和无菌填充等专业服务，他们认识到，在应对复杂的RNA项目时，深厚的技术能力是竞争优势。

合作模式已成为商务策略的核心。技术开发商与大型製药公司之间的策略联盟能够汇集资源，用于后期研发和全球商业化；而学术界与临床机构的伙伴关係能加速转化研究，并为早期临床试验的患者提供便利。有些公司追求垂直整合，以确保关键投入并降低外部供应波动带来的风险；而有些公司则专注于外吐小体分离或聚合物载体化学等细分领域，以提供独特的价值提案。

在这一领域取得成功的公司中，卓越营运的重要性日益凸显。那些早期投资于可扩展分析、稳健的流程控制和监管科学专业知识的公司，能够更有效率地推进临床开发，并更有信心与支付方进行沟通。此外，与监管机构和卫生技术评估机构建立畅通管道的公司，往往能够减少核准阻力，并促进报销谈判。整体而言，业界更青睐那些在生产、监管和商业等各个环节都具备卓越科学领导力和实际执行能力的营业单位。

为高阶主管提供以行动为导向的指导，内容涵盖平台选择、供应链韧性、监管沟通和商业化准备，以加速临床影响。

为了将科学突破转化为持续的治疗效果，产业领导者必须采取务实、协作的行动，平衡创新与营运严谨性。应优先投资于与目标适应症相符的给药平台，并确保製剂选择既符合生物学原理，又符合下游生产的可行性。早期专案应包含分析方法开发和製程表征，以最大限度地减少后期阶段的意外情况，并加快从研究到GMP生产的过渡过程。

增强供应链韧性至关重要。企业应评估关键原料的双重筹资策略，探索区域製造方案以降低跨境风险，并洽谈长期合约以确保取得专用耗材。同时，企业应寻求与合约开发公司和学术中心建立策略合作伙伴关係，以降低技术障碍风险，并在产品组合决策中保持灵活性。

与监管机构、支付方和临床相关人员的沟通应儘早开始，并持续迭代。研发人员应设计能够捕捉监管机构和报销方均关注的终点指标的临床项目，并投资于能够证明长期价值的真实世界证据基础。最后，将临床开发路径与实际运作能力结合，有助于形成严谨的商业化方法，从而确保科学进步能大规模地惠及病患。

我们采用多学科调查方法，结合技术文献综述、监管机构分析、临床註册登记检索和专家访谈，并以透明的方式说明，从而得出可靠的研究结果。

本研究综合了来自同行评审的科学文献、监管指导文件、临床试验註册库、专利概况、生产技术报告以及对行业高管、科学家和伙伴关係专家的访谈证据。透过资料来源的三角验证，检验了技术趋势、给药平台的可行性以及营运限制，从而保持了分析的严谨性。定性访谈为决策流程、合作理由和生产考量提供了背景信息，而二手资料则提供了历史先例和监管演变的参考。

调查方法中采取了多项保障措施，包括由多位专家对技术声明进行交叉检验，根据设施设计文件检验生产和配方方面的挑战，以及仔细研读监管条文以确保对核准流程的准确解读。这种方法优先考虑揭露假设，并透过区分实践模式和瞬时事件，着重关注与营运相关的持续趋势。在整个研究过程中，我们专注于提供可操作的见解，而非推测性的预测，从而使从业人员能够将研究结果直接应用于专案规划和策略决策。

总结性结论强调，要充分发挥RNA技术的治疗潜力，需要将科学创新、製造成熟度和相关人员的参与结合在一起。

RNA疗法正曲折点，技术成熟、临床应用目标不断扩大以及监管预期不断变化，三者汇聚，共同创造了巨大的转化应用机会。持续进展不仅取决于分子设计和递送方式的创新，还取决于企业执行复杂生产宣传活动、管理供应链动态以及与整个医疗生态系统中的相关人员互动的能力。那些将卓越的科学研究实力与前瞻性的营运理念相结合的企业，将更有能力开发出满足未被满足的医疗需求的治疗方法，同时克服商业化和市场准入方面的实际挑战。

随着这一领域的不断发展，平台可重复性、终端用户整合以及证据生成等方面的重点将决定哪些项目能够成功进入临床应用并产生持续的影响。未来几年，融合分子生物学、製剂化学、製程工程和法规科学的多学科团队将在将实验室突破转化为可靠、可扩展的患者疗法方面拥有优势。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 新型脂质奈米颗粒製剂优化了罕见疾病mRNA疫苗的传递与稳定性
  • GalNAc偶联siRNA疗法的日益普及提高了肝病中标靶基因静默的效率。
  • 增加对自扩增RNA平台的投资，以增强低剂量水准的抗原表现。
  • 基于CRISPR的RNA编辑技术的进步加速了体内基因突变的矫正。
  • 扩大分散式製造中心，以实现基于RNA的治疗药物的快速本地化生产
  • 开发耐热mRNA疫苗製剂，以减少新兴市场对低温运输的依赖
  • 生物製药公司与人工智慧公司进行新合作，加速RNA序列设计与递送载体优化。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 RNA疗法市场：依治疗领域划分

  • 心血管疾病
  • 遗传性疾病
  • 感染疾病
    • 细菌感染疾病
    • 病毒感染
  • 代谢紊乱
  • 神经系统疾病
  • 肿瘤学
    • 造血系统恶性肿瘤
    • 固态肿瘤
  • 罕见疾病
    • 高雪氏症
    • 神经肌肉疾病
    • 镰状细胞性贫血症

9. 依递送系统分類的RNA疗法市场

  • 外泌体
  • 脂质奈米颗粒
  • 聚合物载体
  • 病毒载体

第十章 以最终用户分類的RNA疗法市场

  • 生技公司
  • 医院和诊所
  • 製药公司
  • 研究所

第十一章：按地区分類的RNA疗法市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章：RNA疗法市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章：各国RNA疗法市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Moderna, Inc.
    • BioNTech SE
    • Sarepta Therapeutics, Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Ionis Pharmaceuticals, Inc.
    • Arrowhead Pharmaceuticals, Inc.
    • CureVac NV
    • Arcturus Therapeutics Holdings, Inc.
    • Silence Therapeutics plc
    • Stoke Therapeutics
Product Code: MRR-0375F3EAA7E7

The RNA Therapy Market is projected to grow by USD 14.15 billion at a CAGR of 23.55% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.60 billion
Estimated Year [2025] USD 3.23 billion
Forecast Year [2032] USD 14.15 billion
CAGR (%) 23.55%

Comprehensive primer explaining how advancements in RNA modalities, delivery innovations, and regulatory evolution are converging to redefine therapeutic development pathways

The field of RNA therapeutics has moved from scientific curiosity to a central pillar of contemporary biomedicine, reshaping how researchers, clinicians, and industry leaders approach treatment discovery and development. Advances in messenger RNA, small interfering RNA, antisense oligonucleotides, and related modalities have demonstrated therapeutic potential across a wide spectrum of indications, stimulating renewed investment in platform technologies, delivery systems, and specialized manufacturing capabilities. This transition is reflected in accelerated translational pipelines, strategic collaborations between academic institutions and industry, and a growing emphasis on scalable, reproducible production processes.

Technological maturation has been matched by evolving regulatory expectations and clinical evidence requirements, prompting developers to refine trial designs, safety monitoring approaches, and comparator choices. Meanwhile, improvements in delivery vectors, formulation chemistry, and analytical methods have reduced barriers to entry for new developers while raising the bar for differentiation. Consequently, organizations now prioritize platform robustness, cross-indication applicability, and the ability to demonstrate consistent performance across diverse patient populations.

As stakeholders evaluate next steps, the industry must integrate scientific progress with pragmatic operational planning. Manufacturing capacity, supply chain resilience, and regulatory engagement are now as critical as target selection and preclinical efficacy. In short, RNA therapeutics sits at a pivotal juncture where scientific promise must be matched by execution excellence to translate into durable clinical and commercial outcomes.

Detailed analysis of how breakthroughs in delivery platforms, clinical prioritization, and business models are jointly reshaping the RNA therapeutics ecosystem and commercialization strategies

The landscape for RNA therapeutics is undergoing a sequence of transformative shifts that alter strategic priorities for developers and investors alike. First, delivery science has emerged as a primary differentiator: formulations based on lipid nanoparticles and emerging exosome platforms are enabling systemic delivery and tissue targeting that were previously elusive, while polymer carriers and viral vector hybrids offer complementary approaches for sustained expression or localized effect. These delivery advances expand the range of treatable indications, influence dosing paradigms, and materially affect manufacturing requirements.

Second, there is a clear reorientation of clinical focus toward complex and previously intractable indications. Oncology programs increasingly explore RNA-mediated modulation of tumor biology and immune activation for both hematological malignancies and solid tumors, while rare disease efforts harness gene-silencing and replacement strategies to address genetic disorders such as Gaucher disease, neuromuscular disorders, and sickle cell disease. Infectious disease applications, including targeted approaches for viral infections and novel antibacterial RNA strategies, retain strategic importance given global public health priorities and the capability of RNA platforms to accelerate response timelines.

Third, the business model is shifting as platform-centric companies seek to monetize broad technology stacks through licensing, strategic alliances, and vertical integration. Contract development and manufacturing organizations are expanding capabilities to service high-containment production and lipid nanoparticle encapsulation, and hospitals and clinics are beginning to engage with advanced therapies in new ways as clinical delivery paradigms evolve. Research institutes continue to feed innovation, creating a dynamic innovation pipeline that is increasingly interdependent across sectors.

Finally, heightened attention to regulatory and payer evidence is reshaping go-to-market strategies. Developers are investing in real-world evidence generation, longitudinal safety monitoring, and health economics studies that support reimbursement discussions and policy adoption. Taken together, these shifts signal a transition from discrete, proof-of-concept achievements to sustained, system-level integration of RNA therapeutics into clinical practice.

In-depth assessment of how tariff developments can alter supply chains, sourcing strategies, clinical prioritization, and manufacturing investments across RNA therapeutic programs

The potential imposition of cumulative tariffs originating from the United States in 2025 presents a complex set of operational and strategic challenges for organizations involved in RNA therapeutics. Tariff dynamics can increase landed costs for critical raw materials such as lipids, nucleotides, enzymes, and single-use consumables, and they can also affect the availability and pricing of high-value capital equipment used for plasmid production, microfluidic encapsulation, chromatography systems, and sterile fill-finish lines. When procurement costs rise, developers and contract manufacturers are pressured to reassess supplier relationships, inventory strategies, and sourcing geographies to preserve program timelines and maintain quality standards.

In response to tariff-driven cost pressures, companies may accelerate efforts to localize supply chains, expanding domestic production of key inputs or negotiating longer-term procurement agreements to stabilize pricing. While localization can reduce exposure to cross-border tariffs, it often requires significant capital investment and operational lead time, particularly when specialized manufacturing attributes or regulatory approvals are necessary. As a result, smaller developers and research institutes that lack in-house production capabilities may be disproportionately affected, compelling greater reliance on regional contract manufacturers and strategic partners.

Tariffs can also influence clinical development decisions. Increased input costs may cause sponsors to optimize trial designs to reduce material usage per patient, to prioritize indications with clearer pathways to reimbursement, or to sequence programs based on resource intensity. For hospitals and clinics, procurement budgets could be squeezed, potentially affecting adoption cycles for advanced therapies that require complex delivery or supportive infrastructure. Investors and strategic partners will therefore scrutinize the resilience of supply chain plans and the feasibility of production scale-up under altered cost structures.

Finally, the political and regulatory signaling associated with tariff policy can have reputational and strategic implications. Heightened trade tensions may encourage multinational firms to diversify manufacturing footprints across multiple regions to avoid exposure to single-jurisdiction policy shifts. At the same time, bilateral and multilateral dialogues can create pathways for exemptions or tariff mitigation mechanisms for critical healthcare supplies, underscoring the importance of active engagement with policymakers and industry associations. In short, tariff developments in 2025 could catalyze structural adjustments across procurement, manufacturing strategy, and clinical program prioritization, with tangible implications for timelines and partnership models.

Rigorous exploration of therapeutic area distinctions, delivery platform trade-offs, and end-user behaviors that together define program pathways and development priorities for RNA interventions

Segment-level dynamics reveal where scientific opportunity and commercial viability intersect, and they illuminate the tactical choices organizations must confront when advancing RNA-based interventions. Examining therapeutic area segmentation, developers are balancing broad applicability against indication-specific complexity: cardiovascular and metabolic disorder programs pursue systemic delivery and sustained activity, genetic disorder initiatives target precise gene correction or silencing for monogenic conditions, infectious disease strategies differentiate between bacterial approaches and viral infection countermeasures, neurological programs grapple with blood-brain barrier delivery constraints, oncology efforts split between hematological malignancies and solid tumors with differing immuno-oncology considerations, and rare disease pursuits concentrate on specific conditions such as Gaucher disease, neuromuscular disorders, and sickle cell disease where clinical endpoints and regulatory pathways demand bespoke evidence packages. This therapeutic heterogeneity drives divergent development timelines, safety considerations, and commercial access strategies.

When viewed through the lens of delivery system segmentation, contrasts become even more pronounced. Exosome-based strategies promise biologically native delivery and potential immune stealth but face manufacturing and characterization challenges that require advanced analytical capacity. Lipid nanoparticle technologies have become the de facto solution for many systemic applications due to demonstrated scalability and established regulatory precedents, yet they demand rigorous control of excipients and process parameters. Polymer carriers offer tunable release profiles and modular design but frequently require extensive biocompatibility validation, while viral vectors deliver robust transgene expression for certain applications at the cost of immunogenicity and complex regulatory scrutiny. The choice of delivery platform not only affects clinical performance but also determines upstream supplier needs, facility design, and the depth of analytical development required for regulatory submissions.

End-user segmentation shapes commercialization and adoption strategies in practical ways. Biotechnology companies often lead innovation and platform development, focusing on intellectual property creation and clinical proof of concept. Pharmaceutical companies bring late-stage development, regulatory experience, and global commercialization infrastructure, enabling broader market access when clinical and payer evidence align. Hospitals and clinics play a critical role in adoption for therapies that require specialized administration, long-term monitoring, or integration into existing care pathways, and their procurement criteria increasingly emphasize demonstrable clinical benefit and operational feasibility. Research institutes remain essential sources of discovery and translational expertise, frequently partnering with industry to de-risk early science and catalyze new platform iterations.

Taken together, these segmentation insights underscore the necessity of aligning therapeutic targets, delivery choices, and end-user engagement strategies early in program planning. Developers that explicitly account for the interplay among indication characteristics, platform constraints, and end-user requirements are better positioned to design clinical programs that meet regulatory expectations and accelerate acceptance in clinical practice.

Comprehensive regional appraisal of how Americas, EMEA, and Asia-Pacific ecosystems differentially influence innovation, manufacturing capacity, regulatory navigation, and access strategies

Regional dynamics shape the operational calculus for research, development, and commercialization of RNA therapies in distinct ways. In the Americas, robust venture capital ecosystems, leading academic medical centers, and advanced manufacturing infrastructure provide a fertile environment for early-stage innovation and rapid clinical translation. Regulatory pathways administered by national authorities emphasize rigorous safety and efficacy evidence, and the concentration of specialized contract manufacturers and service providers reduces time-to-clinic for programs that can access these networks.

Europe, the Middle East, and Africa present a mosaic of regulatory regimes and payer structures that require nuanced market access planning. The European regulatory framework promotes centralized review pathways that can support cross-border approvals, while health systems across the region emphasize cost-effectiveness and real-world therapeutic value. Emerging markets within the region are experiencing growing biotech activity and clinical trial participation, offering opportunities for enrollment and partnership but necessitating tailored regulatory and reimbursement strategies.

Asia-Pacific is characterized by rapid capacity expansion, substantial public and private investment in biopharmaceutical manufacturing, and an increasing number of skilled scientific and technical personnel. Several jurisdictions are actively streamlining regulatory processes for advanced therapies and incentivizing domestic production, which can accelerate timelines for locally developed programs. Nevertheless, regional supply chain dependencies and variable regulatory harmonization require companies to adopt diversified sourcing approaches and proactive regulatory engagement to ensure smooth program progression across multiple jurisdictions.

Insightful summary of how platform leadership, strategic alliances, manufacturing specialization, and regulatory engagement distinguish the most effective organizations in RNA therapeutics

Leading organizations operating in the RNA therapeutics domain differentiate themselves through a combination of platform depth, strategic partnerships, and manufacturing capabilities. Platform-centric innovators invest in foundational technologies that enable rapid iteration across multiple indications, prioritizing modular design, robust characterization methods, and data packages that support regulatory discussions. Contract developers and manufacturers are expanding specialized services for lipid nanoparticle formulation, analytical method development, and aseptic fill-finish, recognizing that deep technical capability is a competitive advantage when serving complex RNA programs.

Collaborative models have become central to business strategies. Strategic alliances between technology developers and larger pharmaceutical organizations enable resource pooling for late-stage development and global commercialization, while academic and clinical partnerships accelerate translational research and facilitate patient access for early trials. Some organizations pursue vertical integration to secure critical inputs and reduce exposure to external supply volatility, whereas others focus on niche specialization-such as exosome isolation or polymer carrier chemistry-to command unique value propositions.

Operational excellence is increasingly visible in the firms that succeed in this space. Companies that have invested early in scalable analytics, robust process controls, and regulatory science expertise move more efficiently through clinical development and engage payers more credibly. Additionally, those that cultivate open channels with regulators and health technology assessment bodies tend to reduce approval friction and achieve smoother reimbursement discussions. In aggregate, the industry favors entities that combine scientific leadership with pragmatic execution capabilities across manufacturing, regulatory, and commercial functions.

Action-oriented guidance for executives to align platform selection, supply chain resilience, regulatory engagement, and commercialization readiness to accelerate clinical impact

To convert scientific breakthroughs into sustainable therapeutic impact, industry leaders must adopt pragmatic, coordinated actions that balance innovation with operational rigor. Prioritize investment in delivery platforms that align with targeted indications, ensuring that formulation choices are justified by both biological rationale and downstream manufacturing feasibility. Early-stage programs should incorporate analytical development and process characterization to minimize late-stage surprises and to shorten timelines when transitioning from research to GMP production.

Strengthening supply chain resilience is essential. Companies should evaluate dual-sourcing strategies for critical raw materials, consider regional manufacturing options to mitigate cross-border policy exposure, and negotiate long-term agreements that secure access to specialized consumables. Simultaneously, organizations should pursue strategic collaborations with contract developers and academic centers to de-risk technical hurdles while maintaining flexibility in portfolio decision-making.

Engagement with regulators, payers, and clinical stakeholders must begin early and continue iteratively. Developers should design clinical programs that capture endpoints meaningful to both regulators and reimbursement authorities, and they should invest in real-world evidence infrastructures that demonstrate long-term value. Finally, cultivate a disciplined approach to commercialization by aligning clinical development pathways with realistic operational capabilities, thereby ensuring that scientific advances can be delivered reliably to patients at scale.

Transparent description of the multidisciplinary research approach combining technical literature review, regulatory analysis, clinical registry inspection, and primary expert interviews for robust insight generation

This research synthesizes evidence from peer-reviewed scientific literature, regulatory guidance documents, clinical trial registries, patent landscapes, manufacturing technology reports, and primary interviews with industry executives, scientists, and regulatory experts. Analytical rigor was maintained through triangulation across data sources to validate technology trends, delivery platform feasibility, and operational constraints. Qualitative interviews provided context on decision-making processes, partnership rationales, and manufacturing considerations, while secondary sources informed historical precedent and regulatory evolution.

Methodological safeguards included cross-validation of technical claims with multiple domain experts, verification of manufacturing and formulation challenges against facility design documentation, and careful attention to regulatory language to ensure accurate interpretation of approval pathways. The approach prioritized disclosure of assumptions and sought to isolate practice patterns from transient events, thereby focusing on durable trends with operational relevance. Throughout the study, emphasis was placed on actionable insight rather than speculative projection, enabling practitioners to apply findings directly to program planning and strategic decision-making.

Concluding synthesis emphasizing the necessity of combining scientific innovation, manufacturing maturity, and stakeholder engagement to realize the therapeutic potential of RNA technologies

RNA therapeutics stand at an inflection point where technological maturity, expanding clinical ambition, and evolving regulatory expectations converge to create substantial translational opportunity. Continued progress will depend not only on innovations in molecular design and delivery but equally on the ability of organizations to execute complex manufacturing campaigns, manage supply chain dynamics, and engage stakeholders across the healthcare ecosystem. Those that integrate scientific excellence with operational foresight will be positioned to advance therapies that address unmet medical needs while navigating the practical realities of commercialization and access.

As the field progresses, attention to platform reproducibility, end-user integration, and evidence generation will determine which programs achieve clinical adoption and sustained impact. The coming years will likely favor multidisciplinary teams that combine molecular biology, formulation chemistry, process engineering, and regulatory science to convert laboratory breakthroughs into reliable, scalable treatments for patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of lipid nanoparticle formulations optimizing mRNA vaccine delivery and stability for rare diseases
  • 5.2. Growing adoption of GalNAc-conjugated siRNA therapeutics improving targeted gene silencing in liver disorders
  • 5.3. Increased investment in self-amplifying RNA platforms to enhance antigen expression at lower dose levels
  • 5.4. Advances in CRISPR-based RNA editing technologies accelerating in vivo correction of genetic mutations
  • 5.5. Expansion of decentralized manufacturing hubs enabling rapid regional production of RNA-based therapies
  • 5.6. Development of thermostable mRNA vaccine formulations reducing cold chain dependencies in emerging markets
  • 5.7. New collaborations between biopharma and AI firms to accelerate RNA sequence design and delivery vector optimization

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. RNA Therapy Market, by Therapeutic Area

  • 8.1. Cardiovascular Diseases
  • 8.2. Genetic Disorders
  • 8.3. Infectious Diseases
    • 8.3.1. Bacterial Infections
    • 8.3.2. Viral Infections
  • 8.4. Metabolic Disorders
  • 8.5. Neurological Disorders
  • 8.6. Oncology
    • 8.6.1. Hematological Malignancies
    • 8.6.2. Solid Tumors
  • 8.7. Rare Diseases
    • 8.7.1. Gaucher Disease
    • 8.7.2. Neuromuscular Disorders
    • 8.7.3. Sickle Cell Disease

9. RNA Therapy Market, by Delivery System

  • 9.1. Exosomes
  • 9.2. Lipid Nanoparticles
  • 9.3. Polymer Carriers
  • 9.4. Viral Vectors

10. RNA Therapy Market, by End User

  • 10.1. Biotechnology Companies
  • 10.2. Hospitals & Clinics
  • 10.3. Pharmaceutical Companies
  • 10.4. Research Institutes

11. RNA Therapy Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. RNA Therapy Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. RNA Therapy Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Moderna, Inc.
    • 14.3.2. BioNTech SE
    • 14.3.3. Sarepta Therapeutics, Inc.
    • 14.3.4. Alnylam Pharmaceuticals, Inc.
    • 14.3.5. Ionis Pharmaceuticals, Inc.
    • 14.3.6. Arrowhead Pharmaceuticals, Inc.
    • 14.3.7. CureVac N.V.
    • 14.3.8. Arcturus Therapeutics Holdings, Inc.
    • 14.3.9. Silence Therapeutics plc
    • 14.3.10. Stoke Therapeutics

LIST OF FIGURES

  • FIGURE 1. GLOBAL RNA THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS RNA THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL RNA THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. RNA THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RNA THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RNA THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RNA THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RNA THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL RNA THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL RNA THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL RNA THERAPY MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL RNA THERAPY MARKET SIZE, BY GAUCHER DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL RNA THERAPY MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL RNA THERAPY MARKET SIZE, BY SICKLE CELL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL RNA THERAPY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL RNA THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL RNA THERAPY MARKET SIZE, BY POLYMER CARRIERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL RNA THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL RNA THERAPY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL RNA THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL RNA THERAPY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL RNA THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS RNA THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS RNA THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL RNA THERAPY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL RNA THERAPY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. GCC RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GCC RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GCC RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 282. GCC RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 283. GCC RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 284. GCC RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 285. GCC RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 286. GCC RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 287. GCC RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 288. GCC RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 289. GCC RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 290. GCC RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 291. GCC RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. GCC RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPEAN UNION RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. BRICS RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. BRICS RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. BRICS RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 310. BRICS RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 311. BRICS RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 312. BRICS RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 313. BRICS RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 314. BRICS RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 315. BRICS RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 316. BRICS RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 317. BRICS RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 318. BRICS RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 319. BRICS RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. BRICS RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. G7 RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. G7 RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. G7 RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 324. G7 RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 325. G7 RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 326. G7 RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 327. G7 RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 328. G7 RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 329. G7 RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 330. G7 RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 331. G7 RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 332. G7 RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 333. G7 RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. G7 RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. NATO RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 336. NATO RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 337. NATO RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 338. NATO RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 339. NATO RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 340. NATO RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 341. NATO RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 342. NATO RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 343. NATO RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 344. NATO RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 345. NATO RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 346. NATO RNA THERAPY MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 347. NATO RNA THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 348. NATO RNA THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 349. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 350. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 351. UNITED STATES RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 352. UNITED STATES RNA THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 353. UNITED STATES RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 354. UNITED STATES RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 355. UNITED STATES RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 356. UNITED STATES RNA THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 357. UNITED STATES RNA THERAPY MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)